Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.
Jci Insight
Moschos, Stergios J SJ; Sullivan, Ryan J RJ; Hwu, Wen-Jen WJ; Ramanathan, Ramesh K RK; Adjei, Alex A AA; Fong, Peter C PC; Shapira-Frommer, Ronnie R; Tawbi, Hussein A HA; Rubino, Joseph J; Rush, Thomas S TS; Zhang, Da D; Miselis, Nathan R NR; Samatar, Ahmed A AA; Chun, Patrick P; Rubin, Eric H EH; Schiller, James J; Long, Brian J BJ; Dayananth, Priya P; Carr, Donna D; Kirschmeier, Paul P; Bishop, W Robert WR; Deng, Yongqi Y; Cooper, Alan A; Shipps, Gerald W GW; Moreno, Blanca Homet BH; Robert, Lidia L; Ribas, Antoni A; Flaherty, Keith T KT
A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative.
Oncotarget
Pishvaian, Michael J MJ; Joseph Bender, R R; Matrisian, Lynn M LM; Rahib, Lola L; Hendifar, Andrew A; Hoos, William A WA; Mikhail, Sam S; Chung, Vincent V; Picozzi, Vincent V; Heartwell, Craig C; Mason, Kimberly K; Varieur, Katelyn K; Aberra, Metasebia M; Madhavan, Subha S; Petricoin, Emanuel E; Brody, Jonathan R JR